
Bilal Abid, MD, MS
@bilalabidmd
Oncologist | Athlete | Lymphoma | Myeloma | Transplant | Cellular Therapy | Infections | #TxID | CMV | Views personal | RT ≠ endorsements
ID: 1111674891097526272
https://www.medicalsocietymilwaukee.org/News/13182598 29-03-2019 17:02:02
1,1K Tweet
638 Followers
598 Following




“We are going to survive and do the right thing, because doing the right thing is never the wrong thing,” says Dr. Jeff Auletta, followed by applause from attendees. @NMDP



Off-the-shelf CAR-T is here! Our phase 1 trial in Journal of Clinical Oncology shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS ascopubs.org/doi/10.1200/JC…



Concluded the PANAO 2025 conference - M. Bilal Abid Bilal Abid, MD, MS oncodaily.com/blog/concluded… #Cancer #CancerResearch #PANAO #Medicine #MedEd #MedNews #MedX #Health #Conference #Oncology #OncoDaily



Impact of Disparity – Navigating Treatment Equality in Cancer Care - M. Bilal Abid Bilal Abid, MD, MS oncodaily.com/blog/251256 #Cancer #CancerCare #Podcast #CancerTreatment #MedX #MedNews #MedEd #Medicine #Health #Oncology #OncoDaily


SCT rounds caring for patients undergoing stem cell transplantation with Dr Issa Khouri - Sunday morning couldn’t get better! #bmtsm #CARTcell #blessed MD Anderson Cancer Center 🩸


Myeloma Paper of the Day, March 31st, suggested by Robert Orlowski (Robert Z. Orlowski) MD Anderson Cancer Center Muzaffar Qazilbash Bilal Abid, MD, MS oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MyelomaPaperOfTheDay #MultipleMyeloma


Outcomes of patients with multiple myeloma undergoing autoSCT with suboptimal pretransplant response. N=1109 with <VGPR to induction. Median PFS/OS: 38.6/103.8 months Bilal Abid, MD, MS #mmsm #bmtsm onlinelibrary.wiley.com/doi/10.1111/bj…

Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response British Journal of Haematology onlinelibrary.wiley.com/doi/10.1111/bj…

Outcomes of NDMM patients who undergo autoHCT after achieving suboptimal response to induction - Bilal Abid, MD, MS oncodaily.com/url/268413 #NDMM #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #AutoHCT

📜 in Leukemia Journal: “National cancer system metrics and leukemia outcomes: an analysis of global data for pediatric and adult patients” 🙏🏼 Edward Christopher "Chris" Dee, MD Erin Feliciano, MD, MBA Bilal Abid, MD, MS Dr. Tremblay Dr. Singh #leusm 🔗: nature.com/articles/s4137… Expand for a thread on our paper ⤵️


We hope this research serves as a catalyst for #global initiatives to strengthen health systems to improve leukemia outcomes. I am honored to have published this work w/ an amazing team Edward Christopher "Chris" Dee, MD Erin Feliciano, MD, MBA Bilal Abid, MD, MS Dr. Tremblay Dr. Singh 🌎🌍🌏 15/x

“Physician motivation is the biggest driver of successful #ClinicalTrials in community oncology." Bilal Abid, MD, MS outlines how volume, access, staff, & tech-enabled platforms are reshaping trial capacity. bit.ly/4jWKhP4 #COA2025 Community Oncology UTHealth Houston News

Just Published in Transplantation and Cellular Therapy Journal: Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Read more: sciencedirect.com/science/articl…